S-1/A: Apimeds Pharmaceuticals US, Inc. Files for IPO to Advance Bee Venom Therapy

Apimeds Pharmaceuticals US, Inc. is seeking to go public to fund clinical trials for its bee venom-based therapy, Apitox, targeting osteoarthritis and multiple sclerosis symptoms.

Summary

• Apimeds Pharmaceuticals US, Inc., a clinical-stage biopharmaceutical company, has filed an S-1/A registration statement for an initial public offering (IPO).
• The company is developing Apitox, a bee venom-based toxin, for the treatment of osteoarthritis (OA) and multiple sclerosis (MS).
• The IPO aims to raise capital to fund a Phase III clinical trial for knee OA and initiate studies for MS.
• The company plans to offer 3,333,334 shares of common stock with an anticipated initial public offering price between $3.00 and $4.00 per share.
• Inscobee Inc., a South Korean corporation, currently holds approximately 70.27% of Apimeds US's common stock and will hold 50.32% upon completion of the offering.
• Certain existing stockholders have indicated an interest to purchase up to $3.0 million of shares in the offering.
• The company intends to apply for listing on the NYSE American under the symbol APUS.
• Apimeds US believes the OA therapeutics market size in the United States accounted for $8.28 billion in 2022 and it is expected to hit around $20.24 billion by 2032, expanding at a compounded annual growth rate, or CAGR, of 9.4% from 2023 to 2032.
• According to Pharmaceutical Technology the MS market size in the United States accounted for $ 10.73 billion in 2022 and is expected to hit $ 24.4 billion by 2030, expanding at a CAGR of 10.32%.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company highlights the potential of its bee venom therapy and the growing market for OA and MS treatments, it also acknowledges significant risks, including ongoing losses, dependence on related parties, and the need for additional funding. The going concern warning from the auditor further tempers the outlook.

Positives

• Apitox has already been approved in South Korea for treating pain and mobility in OA patients.
• A post-marketing study in South Korea showed no serious adverse events in over 3,000 patients treated with Apitoxin.
• The company has designed a Phase III trial to address FDA standards based on previous trial results.
• Apitox has potential anti-inflammatory and analgesic properties.
• The FDA provides 12-year market exclusivity at the time of approval of a BLA, with the potential for a six-month extension upon approval for pediatric use.

Negatives

• The company has incurred significant net losses since inception and anticipates that it will continue to incur substantial net losses for the foreseeable future and may never achieve profitability.
• The report of the company's independent registered public accounting firm included a going concern explanatory paragraph.
• The company has identified material weaknesses in its internal control over financial reporting, and the failure to remediate these material weakness may adversely affect our business, investor confidence in our company, our financial results and the market value of our common stock.
• The company is substantially dependent on its relationships with Apimeds Korea. The loss of this relationship would have a material adverse effect on our business.
• The company is dependent on the clinical success of Apitox in the treatment of symptoms of knee OA and MS in the United States.

Risks

• Clinical development has inherent risk in its process and our product candidate, Apitox, will be evaluated in a clinical environment for an indication which it has limited patient exposure which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
• The company may require substantial additional funding to finance our operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain parts of our development programs or other operations.
• The company faces significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidate we develop, our commercial opportunities will be negatively impacted. Our product candidate will, if approved, also compete with existing branded, generic and off-label products.
• The company's product candidate may cause undesirable side effects or have other properties that could halt its clinical development, prevent its regulatory approval, limit its commercial potential or result in significant negative consequences. In addition, even if approved, our products may cause significant adverse events, toxicities or other undesirable side effects identified during post-marketing surveillance, which could result in regulatory action or negatively affect our ability to market the product.
• The company relies on principally on trade secrets and other forms of non-patent intellectual property protection, which are difficult to protect.

Future Outlook

The company intends to use the net proceeds from this offering to fund its Phase III clinical trial in knee OA, to initiate at least one non-registered company sponsored trials in MS, manufacturing costs, and any remaining amounts to fund working capital and general corporate purposes.

Industry Context

The announcement highlights the growing market for OA and MS therapeutics, with Apimeds positioning itself to address unmet medical needs in these areas. The company's focus on bee venom-based therapy represents a novel approach in a competitive landscape dominated by traditional pharmaceutical companies.

Comparison to Industry Standards

• The document mentions competitors in the OA and MS markets, including major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
• The document references the Biologics Price Competition and Innovation Act (BPCIA) and the potential for biosimilar competition, indicating awareness of industry standards for biologics development.
• The document references the Most Favored Nation (MFN) Model, indicating awareness of CMS regulatory authority to promulgate regulations and impose other compliance requirements that may increase our compliance costs and impact our ability to attain profitability and market our product candidate.

Related Party Transactions

• The company has entered into a business agreement with Apimeds Korea, a principal stockholder, granting the company a sublicensable, royalty-bearing license to research, develop, manufacture and commercialize and sell Apitox in the United States.
• The company has entered into an intellectual property assignment agreement with Apimeds Korea and Dr. Christopher Kim, the company's Chairman and Chief Medical Officer and the founder of Apimeds Korea.
• The company has entered into a patent license agreement with Dr. Christopher Kim, the company's Chairman and Chief Medical Officer and the founder of Apimeds Korea.
• The company has received cash advances from a related party.
• The company has issued convertible promissory notes to related parties.

Stakeholder Impact

• Shareholders: Potential dilution from the IPO and future equity offerings.
• Employees: Potential for growth and career opportunities if the company is successful.
• Patients: Potential access to a new treatment option for OA and MS symptoms.
• Suppliers: Increased demand for bee venom if Apitox is approved.

Next Steps

• Initiate an additional Phase III trial in advanced knee OA.
• Initiate multiple company sponsored trials in MS to determine the best path to clinical Phase III success.
• Pursue potential collaboration arrangements and out-licensing opportunities.
• Seek non-dilutive funding and grant awards to support our clinical research and product candidate development.

Key Dates

Keywords

Apitox, Apimeds, Pharmaceuticals, Osteoarthritis, Multiple Sclerosis, Clinical Trials, Bee Venom, IPO, Biopharmaceutical